Table 4.
The changes of CM, β-lact, Casein specific IgG1-4 and IgA in the OIT group.
| Characteristics | OIT Group | |||||
|---|---|---|---|---|---|---|
| BL | W8 | W12 | W16 | W24 | W32 | |
| CM-specific | ||||||
| IgG1 level (BUg1/mL) | 1631 (998–2397) | 2004 (909–2262) | 4342** (3308–5844) | 3752** (2328–4581) | 3870** (3397–4963) | 4186** (2957–5555) |
| IgG2 level (BUg2/mL) | 330 (279–482) | 416 (317–5049 | 565** (518–663) | 572** (546–720) | 620** (582–787) | 641** (520–919) |
| IgG3 level (BUg3/mL) | 50 (50–50) | 50 (50–50) | 54 (50–55) | 50 (50–57) | 51 (50-54) | 50 (50–60) |
| IgG4 level (BUg4/mL) | 89 (50–144) | 93 (50–120) | 167 (68–382) | 186* (88–372) | 190* (66-241) | 184* (88–315) |
| IgA level (BUa/mL) | 23 (14–46) | 15 (13-18) | 60* (50–60) | 47** (21–217) | 38 (17–152) | 36 (24–106) |
| β-lact-specific | ||||||
| IgG1 level (BUg1/mL) | 193 (172–199) | 206 (143–252) | 1451** (426–1743) | 1590** (440–1879) | 943** (402–2040) | 1163 (662–1646) |
| IgG2 level (BUg2/mL) | 81 (78–89 | 91 (67–105) | 315** (171–349 | 345** (194–383 | 338** (185–367) | 289** (186–341) |
| IgG3 level (BUg3/mL) | 50 (50–50) | 50 (50–50) | 50 (50–50) | 50 (50–50) | 50 (50–50) | 50 (50–50) |
| IgG4 level (BUg4/mL) | 51 (51–54) | 50 (50–57) | 80 (50–131) | 67* (52–211)* | 90* (52–211) | 110** (58–252) |
| IgA level (BUa/mL) | 12 (10–24) | 10 (9–14) | 25 (17–30) | 23* (11–69) | 19 (10–31) | 18 (13–30) |
| Casein-specific | ||||||
| IgG1 level (BUg1/mL) | 1729 (1205–2813) | 2311 (1199–2480) | 4701** (3564–5685) | 3800** (2533–5072) | 3811** (3475–5482) | 4420** (2822–5676) |
| IgG2 level (BUg2/mL) | 361 (291–490) | 401 (326–515) | 575* (494–673) | 597* (483–702) | 681* (537–757) | 632* (466–911) |
| IgG3 level (BUg3/mL) | 50 (50–50) | 50 (50–50) | 50 (50–76) | 50 (50–53) | 50 (50–58) | 50 (50–68) |
| IgG4 level (BUg4/mL) | 89 (58–154) | 92 (50–129) | 189* (70–228) | 124 (76–228) | 237* ((80–258) | 161* (80–270) |
| IgA level (BUa/mL) | 23 (13–36) | 15 (13–18) | 87** (62–116 | 58** (25–253) | 47 (22–204) | 50* (26–140 |
OIT: oral immunotherapy, CM: cow’s milk, β-lact.: β-lactoglobulin, Each data was express as Median (IQR), transformed as log distribution and that at weeks 8 (W8), 12 (W12), 16 (W16), 24 (W24), and 32 (W32) was compared with that at baseline (BL). *P < 0.05 **P < 0.01.